3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Venous Thromboembolism
5
Neoplasms
2
Thrombosis
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Pulmonary Embolism
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Astrocytoma
1
Interventions
Gemcitabine
45
Cisplatin
34
Oxaliplatin
23
Capecitabine
17
Fluorouracil
13
Leucovorin
12
pembrolizumab
11
lenvatinib
11
durvalumab
10
S 1 (combination)
10
Irinotecan
10
Bevacizumab
8
apatinib
7
Nivolumab
7
tremelimumab
6
Trastuzumab
5
envafolimab
4
atezolizumab
4
Injections
4
Docetaxel
4
trametinib
3
titanium silicide
3
tislelizumab
3
irinotecan sucrosofate
3
camrelizumab
3
Radiotherapy
3
Drug Therapy
3
zanidatamab
2
toripalimab
2
surufatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Biliary Tract Neoplasms
×
apixaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled